beta-Galactosidase

DBCAT003195Pharmacologic class

A group of enzymes that catalyzes the hydrolysis of terminal, non-reducing beta-D-galactose residues in beta-galactosides. Deficiency of beta-Galactosidase A1 may cause GANGLIOSIDOSIS, GM1. A DrugBank category of 1 drug. 1 of them is approved.

Also known as: beta D Galactosidase · beta Galactosidase · beta Galactosidase A1 · beta Galactosidase A2 · beta Galactosidase A3
Drugs: Tilactase

What you can answer from here — as of June 26, 2017

1DrugEach linked to its full drug card

Listed above

1Drug targetEvery drug–target pair in the class, with bond type

18Marketed productsAcross the regions we cover, with dosage forms and routes

1Route of administrationHow the drugs in this class are given

Which targets do beta-Galactosidase share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account